Tag Archives: Biotech

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing

Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.

5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals

5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals

There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.

Cara Therapeutics Stock Has Lost More Than Half Its Value in 2 Weeks

Cara Therapeutics Stock Has Lost More Than Half Its Value in 2 Weeks

On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc. Investment Axim Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome (IBS) with CanChew Plus Cannabidiol (CBD) Chewing Gum

NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.

Axim Biotech - MedChew Rx

AXIM Biotech Enters IBS Clinical Trial for Canchew CBD Chewing Gum

NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.

bq7xic1ceaae77r-pnglarge

New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products

NEW YORK, Nov. 16, 2016 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601.

MJNA and AXIM

Medical Marijuana, Inc. Announces Investment in AXIM Biotechnologies

SAN DIEGO, June 30, 2015 /Weed Wire/ — Medical Marijuana, Inc. (OTC Pink:MJNA) would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies(AXIM), a cutting-edge biotechnology innovator.


Top